Type 1 diabetes is a serious disease that affects how the body controls sugar in the blood. People with this condition cannot produce enough insulin, a hormone that helps move sugar from the blood into the body’s cells for energy.
Without insulin, blood sugar levels rise and can damage many parts of the body. People living with type 1 diabetes must carefully monitor their blood sugar every day and take insulin through injections or pumps in order to survive.
Now researchers in the United States are exploring a new treatment that could change the way this disease is managed. At the Medical University of South Carolina, scientist Leonardo Ferreira is leading a research project that aims to restore the body’s ability to produce insulin again.
The project has received one million dollars in support from Breakthrough T1D, a major international organization that funds research into treatments and cures for type 1 diabetes.
The research team is combining several advanced areas of science, including stem cell biology, immunology, and transplantation medicine. Their goal is ambitious but simple to understand.
They want to replace the insulin‑producing cells that people with type 1 diabetes have lost, and at the same time protect those new cells from being destroyed by the immune system. If successful, the approach could allow patients to produce insulin naturally again without needing drugs that weaken the immune system.
Type 1 diabetes is known as an autoimmune disease. This means the body’s immune system mistakenly attacks its own tissues. In this case, immune cells destroy special cells in the pancreas called beta cells. These cells normally produce insulin. When they are destroyed, the body can no longer regulate blood sugar properly.
About 1.5 million people in the United States live with type 1 diabetes. Over time, high blood sugar can cause serious complications. These may include nerve damage, kidney disease, vision loss, heart disease, and in severe cases coma or death.
Although modern insulin treatments have improved greatly, they do not fully replace the body’s natural ability to control blood sugar.
One possible treatment that doctors sometimes use is islet cell transplantation. In this procedure, doctors transplant insulin‑producing cells from a donor pancreas into a patient. The transplanted cells can begin producing insulin again. However, this approach has two major problems.
The first problem is supply. There are not enough donor pancreases available. In fact, a single transplant often requires cells from several donors. The second problem is immune rejection.
The body’s immune system often attacks transplanted cells because it recognizes them as foreign. Patients must take strong drugs to suppress their immune systems, and these medications can cause serious side effects.
To overcome these challenges, Ferreira and his collaborators are developing a two‑part cell therapy. The first part of the treatment uses stem cells to create new insulin‑producing cells in the laboratory. Stem cells are special cells that can develop into many different cell types in the body. Scientists can guide them to become beta cells that produce insulin.
One of Ferreira’s collaborators, researcher Holger Russ at the University of Florida, specializes in this area of stem cell research. His work focuses on creating large numbers of healthy beta cells in the laboratory so they can be used for research and potential treatments.
The second part of the therapy focuses on protecting these new cells from the immune system. Ferreira studies special immune cells called regulatory T cells, or Tregs. These cells normally help prevent the immune system from attacking the body’s own tissues. In simple terms, they act like peacekeepers that stop the immune system from causing unnecessary damage.
Ferreira’s team is using gene engineering to give these Tregs special receptors called chimeric antigen receptors, or CARs. These receptors help guide the Tregs directly to the transplanted beta cells. Once they arrive, the Tregs act like bodyguards that protect the new insulin‑producing cells from immune attack.
To make this system work, the researchers add a specific protein marker to the beta cells. The engineered Tregs recognize this marker and move toward it. When they attach to the beta cells, they send signals to the immune system telling it not to attack.
In this way, the transplanted beta cells and the engineered Tregs work together. The beta cells produce insulin, while the Tregs protect them from destruction. If this system works as hoped, it could remove the need for lifelong immunosuppressive drugs.
Another advantage of the approach is that laboratory‑grown beta cells could solve the shortage of donor tissue. These cells could be produced in large numbers, frozen, stored, and transported when needed. This could make the treatment available to many more patients in the future.
So far, the researchers have tested their approach in laboratory models, including mice that have been designed to mimic human immune responses. In these early studies, the protective effect of the engineered T cells lasted for about one month. The team is now working to extend this protection and improve how the cells are delivered.
Although the research is still in its early stages, the funding from Breakthrough T1D will allow the scientists to continue refining the therapy and studying how it works. Future research will explore whether repeated treatments could create longer‑lasting protection for the transplanted cells.
The findings from this work have not yet reached human clinical trials, but they represent an important step toward a possible cure. Instead of simply managing blood sugar with insulin, the goal is to restore the body’s natural insulin production.
When reviewing this research, it is clear that the approach is innovative because it combines several powerful technologies.
By using stem cells to create replacement beta cells and engineering immune cells to protect them, the scientists are addressing the two biggest barriers in diabetes transplantation: the shortage of donor cells and immune rejection.
However, many challenges still remain before this therapy can be used in patients. Researchers must determine how long the protective effect lasts, whether the treatment remains safe over time, and how it performs in large human studies. It may take many years before the therapy becomes widely available.
Even so, the study highlights a promising direction for the future of diabetes treatment. If the strategy succeeds, it could move medicine beyond lifelong insulin therapy toward restoring the body’s own ability to control blood sugar.
Such a breakthrough would not only improve the lives of people with type 1 diabetes but could also influence how other autoimmune diseases are treated.
If you care about weight loss, please read studies that hop extract could reduce belly fat in overweight people, and early time-restricted eating could help lose weight .
For more health information, please see recent studies that Mediterranean diet can reduce belly fat much better, and Keto diet could help control body weight and blood sugar in diabetes.
Copyright © 2026 Knowridge Science Report. All rights reserved.
